ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma

Trial Profile

ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Sorafenib (Primary) ; Sunitinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms ASSURE
  • Most Recent Events

    • 05 Jun 2018 Results of a retrospective subgroup analysis of this study, presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 18 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 10 Mar 2016 Primary endpoint has not been met. (Disease-free survival (DFS)), as per results published in the Lancet.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top